trending Market Intelligence /marketintelligence/en/news-insights/trending/bQSCdeqzOTTPrqPWNXKGbQ2 content esgSubNav
In This List

Emergent BioSolutions' chikungunya vaccine gets EMA priority medicines tag

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Emergent BioSolutions' chikungunya vaccine gets EMA priority medicines tag

Emergent BioSolutions Inc.'s chikungunya vaccine CHIKV VLP was granted the priority-medicines designation by the European Medicines Agency.

The vaccine candidate is being developed to prevent chikungunya, which is spread by mosquitoes and causes symptoms such as fever, joint pain and headache. There are no available treatments for the condition, the Gaithersburg, Md.-based life sciences company said in an Oct. 10 press release.

The PRIME designation, granted by the EMA's Committee for Medicinal Products for Human Use, is designed to expedite the development of medicines that target an unmet medical need and which may offer a major therapeutic advantage over existing treatments.

The CHIKV VLP vaccine was also granted the fast-track designation by the U.S. Food and Drug Administration in May 2018.

Emergent BioSolutions develops vaccines for Nipah, anthrax and smallpox virus, among others. In September, the U.S. government signed a 10-year contract potentially worth over $2 billion with the company to buy supplies of its smallpox vaccine for the nation's emergency stockpile.